ALX Oncology (NASDAQ:ALXO – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.15) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.15), Zacks reports.
ALX Oncology Trading Down 3.8%
NASDAQ ALXO opened at $1.00 on Tuesday. The stock has a market capitalization of $138.28 million, a price-to-earnings ratio of -0.88 and a beta of 0.61. The stock’s 50 day moving average price is $1.33 and its two-hundred day moving average price is $1.81. The company has a debt-to-equity ratio of 0.07, a quick ratio of 9.71 and a current ratio of 9.71. ALX Oncology has a 52 week low of $0.86 and a 52 week high of $2.66.
Analyst Upgrades and Downgrades
ALXO has been the topic of a number of research analyst reports. Weiss Ratings upgraded shares of ALX Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 17th. Wall Street Zen lowered shares of ALX Oncology from a “hold” rating to a “sell” rating in a research note on Saturday. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $4.75.
About ALX Oncology
ALX Oncology Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer. Its research centers on the CD47 immune checkpoint, a signal that can help cancer cells evade the immune system. The company’s lead candidate, evorpacept (also known as ALX148), is an investigational CD47-blocking protein designed to support the immune system’s ability to recognize and attack cancer cells. ALX Oncology has studied evorpacept in combination with other cancer treatments across several tumor types.
Read More
- Five stocks we like better than ALX Oncology
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
